Shots:
- Arvinas & Pfizer have reported topline data from ongoing P-III (VERITAC-2) trial of vepdegestrant in ER+/HER2- advanced or metastatic breast cancer pts who had progression with CDK 4/6 inhibitors & endocrine therapy
- Pts received either vepdegestrant (PO, QD) for 28 days or fulvestrant (intramuscular) on Day 1 & 15 of first 28-day cycle, followed by every Day 1 from Cycle 2 onward
- Trial met its 1EP in ESR1m cohort, showing improved PFS, but did not achieve statistical significance in the ITT arm, whereas OS (2EP) data remains immature, with <25% of required events, & is under assessment. Data to be presented at future meetings & shared with global health authorities for potential filings
Ref: Pfizer | Image: Pfizer & Arvinas
Related News:- Pfizer Reports Data from P-III (TALAPRO-2) Trial of Talzenna + Xtandi for Metastatic Castration Resistant Prostate Cancer (mCRPC)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
